Introduction
The present report is concerned primarily with the determination of absorbed dose in a patient irradiated by beams of fast neutrons. The determination of absorbed-dose distributions around 25 2Cf brachytherapy sources (e.g., see Maruyama et al., 1985) , as well as the dosimetry for neutron capture therapy (e.g., see Fairchild and Bond, 1986) , is not considered. In order to compare the clinical results of fast neutron therapy at different institutions, particularly in clinical trials organized by cooperative groups, it is essential to check and to compare the technical irradiation conditions. ICRU Report 26 (ICRU, 1977) treated the methods for determining absorbed dose and kerma of fast neutrons employed for radiobiological and medical applications. Most neutron radiotherapy centers used that report as the main source of information on methodology and basic physical data for neutron dosimetry. However, a number of international neutron dosimetry intercomparisons (e.g., Broerse et al., 1978; ICRU, 1978a) concluded that to reduce differences in quoted absorbed-dose values, it would be necessary to standardize the experimental techniques and that common numerical values of the basic physical parameters should be agreed upon. Considerable effort has, therefore, been made to standardize the dosimetry procedures used in support of the clinical applications of fast neutrons. In the USA, the groups involved in neutron therapy agreed to use a common protocol for neutron beam dosimetry (AAPM, 1980) and a separate protocol was developed in Europe (Broerse et al., 1981) . These protocols are different even though there has been a considerable interchange of ideas and information between the two groups. One of the purposes of this report is to give new recommendations with respect to the values of the basic parameters and experimental techniques employed, based on information now available.
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In high energy photon or electron beam therapy, the RBE does not vary significantly over the energy range used, e.g., see ICRU Report 29 (ICRU, 1978b) and ICRU Report 35 (ICRU, 1984) . In fast neutron radiotherapy, there is a specific problem raised by the fact that the RBE depends on the neutron energy spectrum and on the relative gamma-ray contribution to the absorbed dose, as well as the value of the dose itself. For neutron beams of different energy, the clinical experience and therapeutic protocols can, therefore, only be transferred by taking into account this biological variation. Clinical neutron dosimetry based on the determination of the macroscopic absorbed-dose distribution alone is, therefore, not sufficient. These biological problems related to RBE variations are to be discussed in a separate report.
Different steps can be distinguished in the delivery of absorbed dose to a patient. The main steps in this dosimetry chain are: (1) the determination of the dose at a point in a water phantom under reference conditions; (2) the calculation of the relative dose distribution in a phantom; and (3) the delivery of the radiation to a patient under treatment conditions. A considerable part of the present report (Sections 3-5) is devoted to improving the accuracy and reproducibility in these steps in the dosimetry chain. Consistency in absorbed-dose determinations in individual institutions using neutron beams for therapeutic applications is important and stressed in this report.
Comparison and pooling of clinical data obtained at different institutions must include considerations of radiation quality as well. Section 2, therefore, discusses the experimental methodology and results of neutron energy spectrum measurements of clinical neutron beams. This information is useful for the characterization of the radiation quality of the beam and for the assessment of the values of physical pa-rameters dependent on neutron energy as used in neutron dosimetry. In the same section, microdosimetric characteristics, as well as beam penetration, are considered as alternative descriptions of radiation quality.
A review of dosimetric methods available for clinical neutron dosimetry is presented in Section 3. This section recommends numerical values of physical parameters to be applied in the calibration procedure and in the measurement of absorbed dose in the neutron beam using ionization chambers, and for the use of a reference phantom material. The dosimetric features of other phantom materials, suitable for relative measurements of spatial dose distributions in anthropomorphous phantoms, are also discussed.
Section 4 deals with beam characteristics, such as output, dose build-up, depth dose, and penumbra, that are of importance for the clinical use of fast neutron beams. This section describes the differences in these properties among the clinical neutron beams themselves, as well as differences between clinical neutron and photon beams.
Descriptions of experimental and theoretical methods for the determination of absorbed-dose distributions in patients are given in Section 5. Differences between a patient and an homogeneous phantom are due to (i) kerma differences in the different constituents of the human body irradiated with fast neutrons; and (ii) the effects of body inhomogeneities, as discussed for instance in ICRU Report 13 on absorbeddose distributions (ICRU, 1969) . Correction procedures for the modification of single beam absorbeddose distributions in an homogeneous phantom, with allowance for these inhomogeneities, surface irregularities of the patient and the presence of beam modifying devices, are presented. The combination of sin-gle beams and patient data and a number of typical treatment plans using fast neutron beams are also discussed in this section. Section 5 can, therefore, be considered as an application, for neutron beams, of the principles described for photon beams in some of the sections of ICRU Report 24 (ICRU, 1976) .
Most examples given in this Report are based on work performed with low-energy clinical neutron beams or at facilities built for other purposes and only partly available for clinical work. The new generation of hospital-based machines generally use the p +Be neutron-producing reaction. Because there is considerably more information on physical characteristics as well as patient-related experience from the older facilities, it seemed justified to devote an important part of this Report to clinical neutron dosimetry performed with the older machines. Pooling clinical information from the new p + Be facilities will be easier than with the former low-and high-energy machines. Nevertheless, there will also be problems due to variation in neutron energy with the new beams. Some radiobiological aspects of fast neutron therapy, especially related to specification of beam quality, will be discussed' in a separate Report. In that Report, recommendations for target absorbed-dose specification and reporting of external beam therapy using fast neutrons, alone or as mixed modality treatment, will be given. The present recommendations can be considered as an adaptation for neutrons of those reported in ICRU Report 29 (ICRU, 1978b) for external beam therapy with photons and electrons.
Radiation protection problems associated with patient or staff exposure are not dealt with in this Report. Information on this subject can be found in relevant ICRP and ICRU publications (for example, ICRP, 1977 and ICRU, 1985) .
